Project Grant R21AR081016
Award Date
9/20/23
Completion Date
8/31/25
Dollars Obligated
$354K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55455, USA
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $1,727,423.00 to the University of Iowa over 5 years starting August 7, 2024. The purpose of this research is to investigate the role of the myokine FGF21 in the progression of skeletal abnormalities associated with Duchenne muscular dystrophy (DMD). The project aims to identify the...
This $539,400 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports vascular targeted therapy research for Duchenne muscular dystrophy. The grant was awarded to the Regents of the University of Minnesota, a major land-grant research university, to conduct this cutting-edge biomedical research project. The research aims to develop new treatments and advance scientific understanding of this neurological disorder, which...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to identify myeloid progenitors that maintain cortical bone mass with age and characterize factors that promote coupling within cortical bone. The $375,100 award, active from Sep 20, 2024 to Aug 31, 2026, supports research at the University of Minnesota to address the significant impact of...
This $671,240 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to develop improved gene therapy approaches for Duchenne muscular dystrophy (DMD). The key objectives are to: 1) Refine technologies for expressing larger and more functional dystrophin or utrophin proteins using adeno-associated virus (AAV) vectors, 2) Develop enhanced...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $647,460 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Cornell University to support research on the mechanisms of mechanically-induced gene expression in skeletal muscle cells. The five-year project, running from September 1, 2024 to August 31, 2029, aims to define the nuclear mechanisms responsible for the ultra-rapid activation of mechanoresponsive genes in...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $151,471 to the University of California, Davis to research using collagenase to target collagen architecture in fibrotic skeletal muscle. The goal is to reduce muscle stiffness and promote tissue regeneration, with a focus on improving muscle function and regenerative capacity in...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $1,601,933.00 to the University of Maryland, Baltimore to support research into developing C2 domain therapeutics for muscular dystrophy. The research aims to optimize engineered constructs of the DYSF-C2A domain to rescue deficits in calcium signaling and membrane repair in...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado, operating as the University of Colorado, with a period of performance from July 4, 2024 to August 31, 2027. The funding will support the development of granular hydrogels for the controlled delivery of immunomodulatory and angiogenic extracellular vesicles to enhance...
This $300,477 federal Project Grant award was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training Program (CFDA 93.859). The award will support a 5-year research project focused on investigating the molecular regulation of cell protrusion function in 3D environments. The research aims to develop computational algorithms based on computational geometry to reconstruct plasma membrane organization from 3D microscopy images and...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $551,685 to Duke University to investigate the role of desmosomes, cell adhesion structures, in regulating mRNA localization and translational control. The research aims to determine the molecular mechanisms by which desmosomes recruit mRNAs and translational regulators to the cell...